Group-B type-I Coxsackie virus gene vaccine

A coxsackie virus and gene vaccine technology, applied in the field of vaccines to prevent coxsackie virus infection, can solve the problems of poor safety and poor immunogenicity

Inactive Publication Date: 2006-05-17
HARBIN MEDICAL UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The purpose of the present invention is to provide a kind of Coxsackie virus group B type 1 genetic vaccine for the existing vaccines with poor immunogenicity and poor safety, that is, a genetic vaccine for preventing and treating Coxsackie virus group B type 1 myocarditis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Group-B type-I Coxsackie virus gene vaccine
  • Group-B type-I Coxsackie virus gene vaccine
  • Group-B type-I Coxsackie virus gene vaccine

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0006] Embodiment 1: The CVB1 gene vaccine of this embodiment is a pCEP4-CVB 1VP1 plasmid consisting of the VP1 gene encoding the main neutralizing antigen of CVB1 and the plasmid pCEP4 as a eukaryotic expression vector. For the gene sequence of CVB1VP1, see the gene sequence table.

specific Embodiment approach 2

[0007] Specific implementation mode 2: This implementation mode introduces the CVB1 gene vaccine in detail.

[0008] 1. Materials

[0009] 1.1 Viruses and cells: CVB1 virus strain, Vero cells, HeLa cells and P815 cells were provided by the second diagnostic department of the Institute of Virology, Chinese Academy of Preventive Medicine. s MEM was subcultured, and P815 cells were cultured in RPMI1640 medium.

[0010] 1.2 Vectors and strains: The vectors used in the experiment included pMD18-T, pCEP4, and the host strain of pMD18-T and pCEP4 was JM109. pMD18-T is a product of TaKaRa Biotechnology Company, with a size of 2.7kb. It is a high-efficiency TA cloning vector and is suitable for PCR product cloning. Screen for recombinants. In addition, pMD18-T has M13forward Primer and M13reverse primer at both ends of the multiple cloning site, which is convenient for sequencing the cloned fragments (see figure 1 ). pCEP4 is a product of Invitrogen Company, with a size of 10.4kb....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The group-B type-I coxsackie virus gene vaccine is one kind of vaccine for preventing coxsackie virus infection. The present invention aims at providing CVB1 virus gene vaccine as one kind of pcCEP4-CVB1VP1 plasmid comprising VP1 gene with CVB1 coding main neutral antigen and plasmid pCEP4 as eukaryotic expression vector. Compared with traditional vaccines, the gene vaccine of the present invention has the following advantages: direct DNA inoculation without complicated antigen preparing and purifying process, integrated and lasting immune response with antigen polypeptide submission similar to that in natural infection and no antigen epitope altering, common physical and chemical characteristics with capability of embedding several destination genes in the identical plasmid to form combined vaccine, simple preparation process with low cost and high safety and stability for easy storing and transportation.

Description

technical field [0001] The present invention relates to a vaccine for preventing Coxsackie virus infection. Background technique [0002] Vaccines traditionally used to prevent Coxsackievirus B (CVB) infection include inactivated vaccines and live attenuated vaccines. During the inactivation process of inactivated vaccines, the antigenicity is weakened and important epitopes are lost, so that the body cannot produce sufficient protective immunity. Live attenuated vaccines often cause immunosuppression after inoculation. Insufficient attenuation can lead to clinical virus infection, and live virus vaccines may reverse mutations to produce pathogenic phenotypes, while over-attenuation will reduce the vaccine potency and weaken its efficacy. The ability to stimulate the body's immunity. New CVB vaccines include subunit vaccines and synthetic peptide vaccines. Subunit vaccines are safe, non-toxic, and have few side effects, but poor immunogenicity. In recent years, vaccines ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K39/12
Inventor 田野钟照华赵铁强王言肖建敏孟繁超
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap